Commitment and collaboration
Commitment and collaboration
Commitment and collaboration
Commitment and collaboration
Commitment and collaboration
Commitment and collaboration
Commitment and collaboration
Together, we are committed to making a difference – to patients, the healthcare system and the society in which we are embedded.
Basilea at a glance
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. Basilea has about 150 employees. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands, Cresemba® for the treatment of invasive fungal infections and Zevtera® for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN).
Vision and mission
People are at the heart of everything we do. We strive towards making a difference to patients. With expertise, care and persistence. We aim to be a leading provider of innovative medicines. For the benefit of patients.
Sustainability
By focusing our business on the research and development of novel anti-infectives we contribute to addressing global health priorities – with expertise, care and persistence.
Latest update: August 30, 2024
Materiality analysis
Our goal is to be able to operate successfully in the long term while minimizing negative effects of our activities and contributing to our mission of being a leading provider of innovative medicines for the benefit of patients.
We have performed a materiality analysis that helped us to understand, which environmental, social, governance (ESG) and economic topics matter most in the context of Basilea’s business model. These material topics form the basis of our ESG strategy. They will be key for the setting of goals and are at the core of our future ESG-related reporting.
Concept of “double materiality”
In order to comply with the expectations of our stakeholders, the requirements of EU and Swiss regulations, and the GRI standards (2021), we will publish a regularly updated materiality matrix in our annual sustainability report. In accordance with best practice, we look at each material topic from two different perspectives, using the concept of “double materiality”:
- The “outside-in” perspective: How relevant is a topic for our long-term (business) success?
- The “inside-out” perspective: What is the impact of our business activities in this area?
Process steps
By means of an online survey we collected input from our employees, representing all our business functions. The employees rated the relevance of each topic from both perspectives (outside-in and inside-out). The results of this survey were then consolidated and presented to Basilea’s management committee. To validate the materiality matrix, we held two workshops with the management committee to discuss, evaluate and agree on the final materiality matrix.
Focus topics for our ESG strategy
Our materiality analysis has identified nine topics that are of particular importance either to Basilea’s long-term success and/or to the environment in which we operate. We refer to these areas as focus topics as shown in the materiality matrix below.
These nine focus topics are:
- Product quality and safety
- Antimicrobial resistance
- Animal handling
- Compliance
- Access to medicine
- Intellectual property protection
- Human capital development
- Diversity, equality and inclusion
- Economic performance
We pursue them strategically and aim to make measurable progress against them. In 2024, we further developed our ESG strategy by defining KPIs for the individual focus topics.
As part of our materiality analysis, we have also identified topics that we wish to monitor and, in some cases, actively manage. In the interest of full transparency, we will also disclose these topics in future sustainability reporting.
Basilea’s materiality matrix 2024
Organization
Board of directors
Board committees
Audit committee | Compensation committee | Corporate governance & nomination committee |
Leonard Kruimer (Chairman) | Dr. Martin Nicklasson (Chairman) | Dr. Thomas Werner (Chairman) |
Dr. Martin Nicklasson | Dr. Nicole Onetto | Dr. Carole Sable |
Domenico Scala | Dr. Thomas Werner | Domenico Scala |
For further information on the responsibilities of the board committees, please refer to the latest annual report.
Management committee
Extended management committee